Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Wynne

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
American Journal of Clinical Oncology|October 20, 2021
Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life OutcomesElham Rahimy, Sara A Dudley, Rie von Eyben, et al.
Neuro-Oncology|February 1, 2020
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomesMelissa Azoulay, Steven D Chang, Iris C Gibbs, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life ResultsErqi L Pollom, Dylann Fujimoto, Jacob Wynne, et al.
Practical Radiation Oncology|February 3, 2023
Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant TemozolomideMaria G Mendoza, Melissa Azoulay, Steven D Chang, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
American Journal of Clinical Oncology|October 20, 2021
Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life OutcomesElham Rahimy, Sara A Dudley, Rie von Eyben, et al.
Neuro-Oncology|February 1, 2020
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomesMelissa Azoulay, Steven D Chang, Iris C Gibbs, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life ResultsErqi L Pollom, Dylann Fujimoto, Jacob Wynne, et al.
Practical Radiation Oncology|February 3, 2023
Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant TemozolomideMaria G Mendoza, Melissa Azoulay, Steven D Chang, et al.
Pageof 2